While a recent post hoc analysis focusing on patients who achieved cCR found that the most notable OS improvements were observed in those with t-AML and those aged >70 years [56], its efficacy in the most difficult category (i.e., TP53-mutated or secondary treated AML) remain to be established, with inconsistent results among different reports [53,54,57,58]. The gene discussed is TP53; the disease is acute myeloid leukemia.